Since the Congress' completion, I have heard multiple direct and hearsay comments, emanating from Congress attendees, that were very positive about PV-10. Among them Moffitt researchers, paraphrasing, have never seen a drug work so well. Their comments derive from the cancer center's first hand experience with PV-10 and patients as part of the cancer center's Phase 1 feasibility study. "Well" refers to:
- How well the drug is tolerated. That is, PV-10's pristine safety profile;
- How effective PV-10 is; That is, the drug's efficacy;
- How well the drug ablates. That is, PV-10's ability to significantly shrink or completely eliminate cancerous tumors; and
- How specific PV-10 is; That is, the drug's ability to selectively target and destroy cancer cells without harming surrounding healthy tissue.
Moffitt Cancer Center's ("Moffitt's") peer-reviewed publication in PLoS One, the subject of today's company press release, was published (July 17th) for the start of the Congress. This manuscript is a very newsworthy item. I would expect another high profile item to be released or announced prior to Provectus' participation at the European Cancer Congress ("ECCO") 2013, which runs from September 27th to October 1st.